Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vaccinex stock

Own Vaccinex stock in just a few minutes.

Vaccinex, Inc is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 39 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vaccinex

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VCNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vaccinex share price

Use our graph to track the performance of VCNX stocks over time.

Vaccinex shares at a glance

Information last updated 2021-04-23.
52-week range$1.63 - $9.40
50-day moving average $2.96
200-day moving average $2.54
Wall St. target price$7.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.01

Buy Vaccinex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vaccinex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaccinex financials

Revenue TTM $625,000
Gross profit TTM $-20,926,000
Return on assets TTM -217.18%
Return on equity TTM -748.42%
Profit margin 0%
Book value $-2.30
Market capitalisation $71.1 million

TTM: trailing 12 months

Shorting Vaccinex shares

There are currently 477,891 Vaccinex shares held short by investors – that's known as Vaccinex's "short interest". This figure is 0.9% up from 473,477 last month.

There are a few different ways that this level of interest in shorting Vaccinex shares can be evaluated.

Vaccinex's "short interest ratio" (SIR)

Vaccinex's "short interest ratio" (SIR) is the quantity of Vaccinex shares currently shorted divided by the average quantity of Vaccinex shares traded daily (recently around 937041.17647059). Vaccinex's SIR currently stands at 0.51. In other words for every 100,000 Vaccinex shares traded daily on the market, roughly 510 shares are currently held short.

However Vaccinex's short interest can also be evaluated against the total number of Vaccinex shares, or, against the total number of tradable Vaccinex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccinex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vaccinex shares in existence, roughly 20 shares are currently held short) or 0.0284% of the tradable shares (for every 100,000 tradable Vaccinex shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccinex.

Find out more about how you can short Vaccinex stock.

Vaccinex share dividends

We're not expecting Vaccinex to pay a dividend over the next 12 months.

Vaccinex share price volatility

Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.63 up to $9.4. A popular way to gauge a stock's volatility is its "beta".

VCNX.US volatility(beta: 1.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 1.8181. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Vaccinex overview

Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site